Manjula Ramu, Anuja Kumari, Alcain Francisco J
Department of Pharmacology, Yale School of Medicine, New Haven, CT, United States.
School of Biotechnology, KIIT University, Bhubaneswar, India.
Front Pharmacol. 2021 Jan 12;11:585821. doi: 10.3389/fphar.2020.585821. eCollection 2020.
Sirtuins are NAD dependent histone deacetylases (HDAC) that play a pivotal role in neuroprotection and cellular senescence. SIRT1-7 are different homologs from sirtuins. They play a prominent role in many aspects of physiology and regulate crucial proteins. Modulation of sirtuins can thus be utilized as a therapeutic target for metabolic disorders. Neurological diseases have distinct clinical manifestations but are mainly age-associated and due to loss of protein homeostasis. Sirtuins mediate several life extension pathways and brain functions that may allow therapeutic intervention for age-related diseases. There is compelling evidence to support the fact that SIRT1 and SIRT2 are shuttled between the nucleus and cytoplasm and perform context-dependent functions in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). In this review, we highlight the regulation of SIRT1 and SIRT2 in various neurological diseases. This study explores the various modulators that regulate the activity of SIRT1 and SIRT2, which may further assist in the treatment of neurodegenerative disease. Moreover, we analyze the structure and function of various small molecules that have potential significance in modulating sirtuins, as well as the technologies that advance the targeted therapy of neurodegenerative disease.
沉默调节蛋白是依赖烟酰胺腺嘌呤二核苷酸(NAD)的组蛋白脱乙酰酶(HDAC),在神经保护和细胞衰老中起关键作用。SIRT1 - 7是沉默调节蛋白的不同同源物。它们在生理学的许多方面发挥着重要作用,并调节关键蛋白质。因此,调节沉默调节蛋白可作为代谢紊乱的治疗靶点。神经疾病有不同的临床表现,但主要与年龄相关,且是由于蛋白质稳态丧失所致。沉默调节蛋白介导多种延长寿命的途径和脑功能,这可能为与年龄相关的疾病提供治疗干预。有令人信服的证据支持这样一个事实,即SIRT1和SIRT2在细胞核和细胞质之间穿梭,并在包括阿尔茨海默病(AD)、帕金森病(PD)和亨廷顿舞蹈病(HD)在内的神经退行性疾病中发挥依赖于环境的功能。在这篇综述中,我们重点介绍了SIRT1和SIRT2在各种神经疾病中的调节作用。本研究探索了调节SIRT1和SIRT2活性的各种调节剂,这可能进一步有助于神经退行性疾病的治疗。此外,我们分析了在调节沉默调节蛋白方面具有潜在意义的各种小分子的结构和功能,以及推进神经退行性疾病靶向治疗的技术。
Front Pharmacol. 2021-1-12
EMBO Mol Med. 2013-2-18
Cureus. 2023-6-15
Neurochem Res. 2017-3
Curr Drug Targets. 2013-6-1
Eur J Pharmacol. 2019-12-5
Front Cell Neurosci. 2022-6-22
Ageing Res Rev. 2024-12
Mol Cell Biochem. 2025-5-13
Molecules. 2020-7-20
Aging (Albany NY). 2020-4-20
Front Neurosci. 2020-1-29
Front Aging Neurosci. 2020-1-10
Phys Chem Chem Phys. 2020-1-2